The FDA has approved nilotinib tablets (Danziten) for patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (CML) in chronic phase, as well as those with resistance or intolerance to prior therapy, including imatinib (Gleevec). Developed by Azurity Pharmaceuticals, Inc., this new formulation of nilotinib does not require mealtime restrictions, addressing a significant limitation of the original nilotinib formulation (Tasigna).
The original formulation of nilotinib (Tasigna) has variable bioavailability, which increases when taken with food. This can lead to a significant QT prolongation interval on surface electrocardiogram, potentially causing cardiotoxicity. Consequently, strict fasting was enforced to mitigate this risk. Danziten overcomes this issue, offering equivalent efficacy without the need for fasting.
Clinical Impact and Convenience
Richard Blackburn, chief executive officer of Azurity Pharmaceuticals, Inc, stated that Danziten offers a new nilotinib treatment option with equivalent efficacy to Tasigna, but without the fasting requirements. He emphasized that the boxed warning on the Danziten label does not require patients to take their medication in a fasted state, liberating patients with CML from mealtime restrictions.
This approval marks a significant advancement in CML treatment, enhancing patient convenience and potentially improving adherence to therapy. The elimination of mealtime restrictions can positively impact patients' quality of life, making it easier to manage their medication schedule alongside their daily routines.
